Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb & Co's (NYSE: BMS) Opdivo (nivolumab).
Data were presented at the ASCO 2021 Annual Meeting.
COM701 and Opdivo combination was well-tolerated with no reported dose-limiting toxicities up to the fifth and final dose cohort.
The disease control rate (DCR) was 66.7% with best responses of complete response (CR) 6.7%, partial response (PR) 6.7% (N=1) and stable disease (SD) 53.3%.
Previously reported patient with anal squamous cell carcinoma with confirmed CR remains on treatment at 96 weeks (22 months).
Previously reported patient with renal cell carcinoma with the best response of SD remains on treatment at 75 weeks.
A patient with microsatellite stable (MSS)-colorectal cancer with durable confirmed partial response previously reported remained on study treatment for 44 weeks.
In monotherapy arm, DCR was 47.2% (N=17) with best responses of PR 2.7% (N=1) and SD) 44.4% (N=16).
Previously reported patient with primary peritoneal cancer (platinum-resistant, MSS) with confirmed PR remains on study treatment at 79 weeks (18 months).
Peripheral blood assessment showed immune activation as measured by immune cell proliferation and IFNγ induction before tumor shrinkage.
Price Action: CGEN shares are up 0.76% at $8 during the premarket session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.